FDA approves first in class targeted therapy for metastatic pancreatic cancer

	FDA approves first in class targeted therapy for metastatic pancreatic cancer(fda.gov)
	278 points by leopoldj 60 days ago \| 71 comments
	tl;dr: Summary not available
	HN Discussion: ↑Personal stories of losing loved ones to pancreatic cancer, welcoming any new treatment progress ↑Scientific excitement about targeting KRAS, a historically undruggable protein with broad cancer implications ↑Notable praise for the FDA's unusually fast approval timeline via the CNPV Pilot Program ↑The survival improvement statistics (13.2 vs 6.7 months) represent meaningful progress for a dire disease •Reflection on mortality and the humane trade-offs of different ways to die